Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Stribild regulatory update

February 3, 2017 12:41 AM UTC

FDA approved an sNDA from Gilead for Stribild elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate to treat HIV-1 infection in pediatric patients ages ≥12 weighing ≥35 kg. The drug is approved in adults who have no history of antiretroviral therapy (ART) or as replacement therapy for virologically suppressed patients on a stable ART regimen for ≥6 months with no history of treatment failure and no known substitutions associated with resistance to Stribild’s components. Stribild is a once-daily tablet comprising Vitekta elvitegravir and Gilead’s Tybost cobicistat and Truvada emtricitabine/tenofovir...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article